Refine your search
Collections
Co-Authors
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Patil, Shrikant
- Non-Familial Retinoblastoma:Case Report
Abstract Views :200 |
PDF Views:81
Authors
Mahesh Ahirrao
,
Bhagyashree Ahirrao
,
Prashant Bhadane
,
Sanjay Joshi
,
Jagdish Pakhare
,
Shrikant Patil
Source
MVP Journal of Medical Sciences, Vol 2, No 2 (2015), Pagination: 128-129Abstract
Retinoblastoma is a malignancy of the retina. It is most common intraocular tumor in children. Dominantly inherited disorder frequently found association with defect in RB1 gene. Approximately 40% of patients with retinoblastoma have inherited a germ-line mutation of the RB1 gene found 10% unilaterally while 60% are non-familial. Herewith we present 2 cases of non-familial, unilateral retinoblastoma.Keywords
Non-Familial, Retinoblastoma, Sporadic.Full Text
References
- Nelson textbook of Pediatrics. 19th ed. Vol II. p. 1768-9.
- Tucker T, Friedman JM. Pathogenesis of hereditary tumors: beyond the “two-hit” hypothesis. Clin Genet. 2002; 62(5):345-57.
- Sippel KC, Fraioli RE, Smith GD, et al. Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling. Am J Hum Genet. 1998; 62(3):610-9.
- Murphree LA. Intraocular retinoblastoma: the case for a new group classification. Ophthalmol Clin North Am. 2005; 18(1):41-53.
- Goodrich DW. The retinoblastoma tumor-suppressor gene, the exception that proves the rule. Oncogene. 2006; 25(38):5233-43.
- Knudson AG Jr, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. ProcNatl Acad Sci U S A. 1975; 72(12):5116-20.
- Smith JH, Murray TG, Fulton L, O’Brien JM. Siblings of retinoblastoma patients: are we underestimating their risk? Am J Ophthalmol. 2000; 129(3):396-8.
- Munier FL, Wang MX, Spence A, et al. Pseudo low penetrance in retinoblastoma: fortuitous familial aggregation of sporadic cases caused by independently derived mutations in two large pedigrees. Arch Ophthalmol. 1993; 111(11):1507-11.
- Role of Antihistamine and Leukotriene Receptor Antagonist in Allergic Rhinitis Management: Newer Perspectives
Abstract Views :128 |
PDF Views:86
Authors
Affiliations
1 President- Medical & Regulatory Affairs, IN
2 Deputy General Manager- Medical, Scientific Department, IN
3 Manager- Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, India., IN
1 President- Medical & Regulatory Affairs, IN
2 Deputy General Manager- Medical, Scientific Department, IN
3 Manager- Scientific Department, Aristo Pharmaceuticals Private Limited, Mumbai, India., IN
Source
The Indian Practitioner, Vol 75, No 6 (2022), Pagination: 28-34Abstract
Allergic disorders are conditions induced by the immune system’s hypersensitivity to normally harmless chemicals known as allergens. The most common allergens include dust mites, pollution, grass pollens and food allergens such as milk, egg, soy, wheat, nut, or fish proteins. Allergic diseases include allergic rhinitis (AR), allergic asthma, urticaria, atopic dermatitis, contact allergies and food allergies. AR is the most common of all atopic diseases, afflicting 10%–30% of adults and up to 40% of children all over the world. The mechanisms underlying AR are highly complex and involve multiple immune cells, mediators and cytokines such as histamine and leukotrienes. It is characterized by nasal symptoms such as sneezing, nasal itching, rhinorrhea, and nasal congestion. It is also, associated with non-nasal symptoms such as watery eyes, redness in the eyes or inflammation. It has a significant effect on one’s health, as well as the quality of one’s sleep, work productivity and academic performance. The management of AR includes allergen avoidance, pharmacotherapy, and immunotherapy. Complete avoidance of allergens that trigger AR symptoms is not possible. Current pharmacologic options include antihistamines (oral and intranasal), Leukotriene Receptor Antagonists (LTRAs), Intranasal Corticosteroids (INCS), decongestants and oral and intranasal anticholinergics. Amongst other antihistamines, Bilastine has emerged as a new, non-sedating and well-tolerated antihistamine while Montelukast is an effective add-on LTRA option to an antihistamine with well-established literature in the management of moderate-severe AR. Immunotherapy is a treatment option for patients who have not responded to medication.
Keywords
Allergic rhinitis, antihistamines, LTRAs, montelukast, bilastineFull Text
References
- Pawankar R, Mori S, Ozu C, Kimura S. Overview on the pathomechanisms of allergic rhinitis. Asia Pac. Allergy. 2011;1:157-167.
- Kim H, Bouchard J, Renzi P M. The link between allergic rhinitis and asthma: A role for antileukotrienes? Can Respir J.2008;15(2):91-98.
- Bhargava S, Sheth K, Bharathi MB, Dabholkar Y, Pendakur A, Desai A, et al. Indian guidelines on diagnosis and mange ment of Allergic Rhinitis- A consensus approach.
- Pawankar R, Canonica GW, Holgate ST, Lockey RF, Blaiss MS. World Allergy Organization (WAO) White Book on Allergy: Update. 2013.
- Chandrika D. Allergic rhinitis in India: an overview. Int J Otorhinolaryngol Head Neck Surg. 2017;3(1):1-6.
- Valovirta E. Pawankar R. Survey on the impact of comorbid allergic rhinitis in patients with asthma. BMC Pulm. Med.2006;6:1–10.
- Bjermer L, Westman M, Holmstrom M, Wickman MC. The complex pathophysiology of allergic rhinitis: Scientific rationale for the development of an alternative treatment option. Allergy, Asthma Clin. Immunol.2019;15:1–15.
- Giavina BP, Aun MV, Takejima P, Kalil J, Agondi RC. United airway disease: current perspectives. Journal of Asthma and Allergy.2016;9:93–100.
- Jaggi V, Dalal A, Ramesh BR, Tikkiwal S, Chaudhry A, Kothari N,et al. Coexistence of allergic rhinitis and asthma in Indian patients: The CARAS survey. Lung India.2019;36:411-6.
- Bergeron C, Qutayba H. Relationship between Asthma and Rhinitis: Epidemiologic, Pathophysiologic, and Therapeutic Aspects. Allergy, Asthma, and Clinical Immunology.2005; 1(2):81-87.
- Small P, Keith PK, Kim H. Allergic rhinitis. Allergy, Asthma and Clinical Immunology.2018;14(2):31-41.
- Heinzerling L, Mari A, Bergmann KC, Bresciani M, Burbach G, Darsow U, et al. The skin prick test – European standards. Clinical and Translational Allergy.2013;3:3.
- Min YG. The Pathophysiology, Diagnosis and Treatment of Allergic Rhinitis. Allergy, Asthma Immunol Res. 2010;2(2):6576.
- Pawankar R, Bunnag C, Chen Y, Fukuda T, Kim YY, Tuyet Le LT, et al. Allergic Rhinitis and its impact on asthma update (ARIA 2008) - Western and Asian-Pacific Perspective. Asia Pacific Journal of Allergy and Immunology.2009;27:237-243.
- Krouse JH. Allergic Rhinitis- Current Pharmacotherapy. Otolaryngol Clin N Am. 2008;41:347–358.
- Hossenbaccus L, Linton S, Garvey S, Ellis AK. Towards definitive management of allergic rhinitis: best use of new and established therapies. Allergy, Asthma Clin Immunol.2020;16:39.
- Ridolo E, Montagni M, Bonzana L, Incorvaia C, Canonica GW. Bilastine: New insight into antihistamine treatment. Clinical and Molecular Allergy.2015;13:1.
- Valk PJ, Simons RM, Valiente R, Labeaga L. Cognitive Performance Effects of Bilastine 20 mg During 6 Hours at 8000 ft Cabin Altitude. Aerospace Medicine and Human Performance. 2016;87(7):622-627.
- Horak F. Effectiveness of twice daily azelastine nasal spray in patients with seasonal allergic rhinitis. Therapeutics and Clinical Risk Management 2008;4(5):1009–1022.
- Yu Xu, Zhang J, Wang J. The Efficacy and Safety of Selective H1-Antihistamine versus Leukotriene Receptor Antagonist for SeasonalAllergic Rhinitis: A Meta-Analysis.PLOS ONE.2014;9(11):e112815.
- Okubo K, et al. Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study. Allergology International.2016:1-9.
- Kuna P, Bachert C, Nowacki Z, Cauwenbergew P, Agache I, Fouquert L, et al. Efficacy and safety of bilastine 20 mg compared with cetirizine 10 mg and placebo for the symptomatic treatment of seasonal allergic rhinitis: a randomized, double-blind, parallel-group study. Clinical & Experimental Allergy.2009;39:1338–1347.
- Bachert C, Kuna P, Sanquer F, Ivan P, Dimitrov V, Gorina M, et al. Comparison of the efficacy and safety of bilastine 20 mg vs desloratadine 5 mg in seasonal allergic rhinitis patients. Allergy.2009: 64: 158–165.
- Rajput MS, Arain AA, Rajput AA, Mohammad A, Ghaffar S, et al. Effect of montelukast on the Symptom Severity Score of Allergic Rhinitis. Cureus12(3):e7403.
- Philip G, Malmstrom K, Hampel FC, Weinstein SF, LaForce CF, Ratner PH, et al. Montelukast for treating seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial performed in the spring. Clin Exp Allergy. 2002;32:1020- 1028.
- Dapagliflozin and Neuro-Nutrition: A Pragmatic Approach to Manage Diabetic Peripheral Neuropathy
Abstract Views :54 |
PDF Views:0
Authors
Affiliations
1 President-Medical & Regulatory Affairs, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Deputy General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
3 Assistant General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
1 President-Medical & Regulatory Affairs, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, Mumbai, IN
2 Deputy General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
3 Assistant General Manager-Medical, Dept. of Scientific, Aristo Pharmaceuticals Private Limited, IN
Source
The Indian Practitioner, Vol 76, No 2 (2023), Pagination: 28-30Abstract
Diabetic peripheral neuropathy (DPN) is the most prevalent microvascular complication of diabetes mellitus. DPN results from a complex interaction of factors including hyperglycemia, glucotoxicity, increased intracellular glucose concentration-induced mitochondrial dysfunction, oxidative stress, etc. A multifaceted approach is warranted for the clinical treatment of DPN. Combination therapy of an antidiabetic agent along with neuro-nutrition aimed at addressing the pathogenic features of neuropathy can be a potential treatment option for effective management of DPN.Keywords
Type 2 Diabetes (T2DM), Diabetic Peripheral Neuropathy (DPN), Dapagliflozin, Neuro-Nutrition, B-Group Vitamins, Neuroprotection.
References
- Zimmet PZ, Diabetes and its Drivers: the Largest Epidemic in Human History? Clin. Diabetes Endocrinol;p.3 (1), 1–8.
- IDF. Diabetes Facts & Figures, the IDF Diabetes Atlas Ninth Edition 2019.
- Bromberg MB, An Approach to the Evaluation of Peripheral Neuropathies. Seminars in Neurology, 25. p. 153-159.
- Maladkar M, Tekchandani C, Dave U; Post-Marketing Surveillance of Fixed Dose Combination of Methylcobalamin, Alpha Lipoic Acid, Folic Acid, Biotin, Benfotiamine & Vitamin B6-Nutripathy for the Management of Peripheral Neuropathy. Journal of Diabetes Mellitus 4. p. 124-132.
- Pugazhenthi S, Qin L, Reddy PH; Common Neurodegenerative Pathways in Obesity, Diabetes, and Alzheimer’s Disease. Biochim. Biophys. Acta Mol. Basis Dis. 1863 (5). p.1037–1045.
- Boulton AJ, Diabetic Neuropathy and Foot Complications. Handb. Clin. Neurol 126. p.97–107. doi:10.1016/B978-0-444-53480-4.00008-4
- Kandeel M. The Outcomes of Sodium-Glucose Co-transporter 2 Inhibitors (SGLT2I) on Diabetes-Associated Neuropathy: A Systematic Review and meta-Analysis. Front Pharmacol. 2022 Jul 11;13 p 926717.
- Sa-Nguanmoo P, Tanajak P, Kerdphoo S, et al. SGLT2-inhibitor and DPP-4 Inhibitor Improve Brain Function via Attenuating Mitochondrial Dysfunction, Insulin Resistance, Inflammation, and Apoptosis in HFD-Induced Obese Rats. Toxicol. Appl. Pharmacol. 333, p 43–50.
- Duby JJ, Campbell RK, Setter SM, et al. (2004) Diabetic neuropathy: an intensive review. Am J Heal Pharm 61:160–176.
- Cameron NE, Eaton SEM, Cotter MA, et al. (2001) Vascular factors and metabolic interactions in the pathogenesis of diabetic neuropathy. Diabetologia 44, p 1973–1988.
- Obrosova IG (2002) How does glucose generate oxidative stress in peripheral nerve? Int Rev Neurobiol 50, p 3–35.
- World Health Organization (2006) Neurological Disorders: Public Health Challenges. World Health Organization, p 111-174.
- Kumar N. Nutritional Neuropathies. Neurologic Clinics, 25, p 209-255.
- Luo J.J, Sivaraaman K, Nouh A. et al. Elevated Plasma Level of Homocysteine Is an Independent Risk Factor for Peripheral Neuropathy. British Journal of Medicine & Medical Research, 4, p 161-169.
- Caiqin W, Hui P, Wenli W. et al. Effect Of Dapagliflozin Combined With Mecobalamin On Blood Glucose Concentration And Serum MDA, SOD, And Cox-2 In Patients With Type 2 Diabetes Mellitus Complicated With Peripheral Neuropathy. Acta Medica Mediterranea, 35, p 2211.
- Wiciński M, Wódkiewicz E, Górski K, et al. Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer’s Disease and Ischemia-Related Brain Injury. Pharmaceuticals 2020 Nov 11;13(11) p 379. doi: 10.3390/ph13110379.
- Sun Y, Lai MS. Lu CJ. Effectiveness of Vitamin B12 on Diabetic Neuropathy: Systematic Review of Clinical Controlled Trials. Acta Neurologica Taiwanica, 2005 Jun;14(2). p 48-54.
- Stracke H, Lindemann A, Federlin K. A Benfotiamine-Vitamin B Combination in Treatment of Diabetic Polyneuropathy. Experimental and Clinical Endocrinology & Diabetes, 1996;104(4). p 311-6. doi: 10.1055/s-0029-1211460.